Menu
Search
|

Menu

Close
X

Axovant Sciences Ltd AXON.OQ (NASDAQ Stock Exchange Global Select Market)

2.46 USD
-0.11 (-4.28%)
As of Jul 20
chart
Previous Close 2.57
Open 2.61
Volume 225,421
3m Avg Volume 778,190
Today’s High 2.61
Today’s Low 2.45
52 Week High 27.93
52 Week Low 1.02
Shares Outstanding (mil) 107.53
Market Capitalization (mil) 758.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.066
FY17
-1.825
FY16
-1.371
FY15
-0.221
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
3.67
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
25.10
16.84
LT Debt to Equity (MRQ)
vs sector
25.10
12.51
Return on Investment (TTM)
vs sector
-85.17
14.61
Return on Equity (TTM)
vs sector
-95.04
16.34

EXECUTIVE LEADERSHIP

Vivek Ramaswamy
Chairman of the Board, Since 2018
Salary: $360,500.00
Bonus: $200,528.00
Pavan Cheruvu
Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Gregory Weinhoff
Chief Financial Officer, Since 2015
Salary: $360,500.00
Bonus: $200,528.00
Mark Altmeyer
President of Axovant Sciences GmbH and Chief Commercial Officer, Since
Salary: $322,917.00
Bonus: $161,458.00
Eric Floyd
Senior Vice President - Regulatory Affairs, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

20-22 Bedford Row
LONDON     WC1R 4JS

Phone: +441295.5950

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.

SPONSORED STORIES